AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05528718 — intervention group
Intervention type: DRUG
Intervention: Nitrous oxide gas for inhalation
Description: This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
Study NCT05528718 — intervention group
Intervention type: DRUG
Intervention: Midazolam injection
Description: This sub-study does not have an intervention and based on the main study the participants who have received N2O will be compared with the midazolam placebo group.
Study NCT05842785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I dose escalation
Description: The eligible subjects will receive TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Study NCT05842785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II-HNSCC
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Study NCT05842785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II-Advanced melanoma
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Study NCT05842785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II-solid tumors or lymphomas
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Study NCT04748445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2/Influenza/RSV RT-PCR
Description: nasal swab
Study NCT05233943 — intervention group
Intervention type: DEVICE
Intervention: Spinal Mouse and Digital Inclinometer
Description: The spinal mouse device is non-invasive and does not have any danger. The posture is evaluated by moving from top to bottom on the spine of the person. Data on the device is transferred to the computer via Bluetooth. The person's posture is evaluated in the sagittal plane by making maximum flexion, neutral stance and maximum extension positions, and in the frontal plane by lateral flexion to the right and left.~Digital Inclinometer; It is a non-invasive measurement tool that investigators measure the position sense of the body, which has two parts, one fixed and one movable. The immobile part of the digital inclinometer is placed at the sacrum and the movable part is placed at the T4 spine level. The person is made 30 degrees of trunk flexion. Then, he is expected to perform 5 repetitions of 30 degrees of trunk flexion with his eyes closed. Deviation angles are recorded.
Study NCT06291662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printer applications
Description: Patients will undergo TC/MRI as per routinary care. Custom 3D-devices will be printed on the basis of these images. The device will be used to establish pre-operative surgical options in terms of tissue/bones demolition/reconstruction.
Study NCT06333210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-TRBV9 monoclonal antibody infusions
Description: infusions
Study NCT06333210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusions
Description: infusions
Study NCT06333210 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusions
Description: infusions
Study NCT06333210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab subcutaneous injection
Description: subcutaneous injection
Study NCT06333210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo subcutaneous injection
Description: subcutaneous injection
Study NCT06333210 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous injection
Description: subcutaneous injection
Study NCT06481852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTT with antibiotic preconditioning + fiber supplementation
Description: MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
Study NCT06481852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTT with antibiotic preconditioning + placebo supplementation
Description: MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
Study NCT06481852 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MTT with placebo + placebo supplementation.
Description: MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
Study NCT05288725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Derived MSCs
Description: Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.
Study NCT05288725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog \[40 mg/dL\], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.
Study NCT05288725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.
Study NCT05288725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspirate
Description: The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.
Study NCT05480670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 550 mg Berberine supplement BDS for 3-months + changes in diet/life style.
Study NCT06028035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BB01
Description: 20 grams minimally processed form of Hemp hulls in the form of a bar/wafer.
Study NCT05651360 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: low-dose CT
Description: Low-dose CT scan will be performed, not exceeding 30% radiation dose of the standard CT. Low-dose CT images will be reconstructed with TrueFidelity high. The low-dose CT will be performed directly after the standard CT to avoid bias from differences in the timing of the contrast phase.
Study NCT05923086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORE001
Description: Administration before major meal
Study NCT05923086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration before major meal
Study NCT05360030 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Naloxone
Description: The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session
Study NCT05360030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session
Study NCT05360030 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session
Study NCT05360030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session
Study NCT05360030 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session
Study NCT05360030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session
Study NCT05360030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pcTBS of M1
Description: Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
Study NCT05360030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pcTBS of DLPFC
Description: Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left DLPFC at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline
Study NCT05360030 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM stimulation
Description: The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
Study NCT05254444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social marketing
Description: Multi-tiered nutrition social marketing intervention focused on sustainable fish nutrition, dietary diversity and food safety.
Study NCT05254444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social marketing + gear modification
Description: Multi-tiered nutrition social marketing intervention plus fishing gear modification (basket trap) and training.
Study NCT06023602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic cetrorelix acetate
Description: Generic cetrorelix acetate (0.25 mg SC)
Study NCT06023602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference cetrorelix acetate
Description: reference cetrorelix acetate (0.25 mg SC)
Study NCT05452499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education and therapeutic exercise
Description: Participants will receive a 9-week physiotherapy program. Consisting of 3 sessions of pain neuroscience education and 24 sessions of therapeutic exercise (16 face-to-face sessions and 8 at home).
Study NCT05121103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZM0414
Description: Immediate-release film-coated tablets: Six dose levels starting at 100 mg, and then 200 mg, 300 mg, 400 mg, 600 mg, and 900 mg as well as an optional step-down dose level of 75 mg (if needed)
Study NCT05896566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.
Study NCT04715919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chest Computed Tomography
Description: Evaluation of Lung Structure
Study NCT04715919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests
Description: Respiratory Capacity
Study NCT04715919 — intervention group
Intervention type: OTHER
Intervention: Six Minutes Walk Test
Description: Exercise Capacity
Study NCT05896566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin: 3.75 mg IM on day 1. Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
Study NCT05896566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Triptorelin: 3.75 mg IM on day 1. Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
Study NCT05896566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole: 1 mg daily, PO from day 1 until the day of re-biopsy/surgery.
Study NCT04715919 — intervention group
Intervention type: OTHER
Intervention: Quality of Life
Description: Physical disability assessment tool
Study NCT05563363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-like treatment in patients' home
Description: Hospital-like treatment in patients' home. Caregivers, medical doctors and social workers will make several visits per day to the patients' home. 24/7 contact is available.
Study NCT05563363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard inpatient treatment
Description: Inpatient treatment on addiction ward
Study NCT05796180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: sexual health counseling based on the BETTER model
Description: The content of the research will be discussed by face-to-face interviews with women who gave birth vaginally and applied to the hospital for birth control 8-10 weeks after delivery. Pre-evaluation forms will be applied to women who have agreed to participate in the study to evaluate the inclusion criteria. Women who meet the inclusion criteria will be divided into experimental-control groups using the block randomization method.~An appointment will be made for interviews with the women in the experimental group. It is planned that these meetings will be held in the form of online video calls and will last an average of 45 minutes. The final tests will be held 8 weeks after the online meetings are over.
Study NCT05023135 — intervention group
Intervention type: DEVICE
Intervention: DeepView SnapShot Portable (DV-SSP)
Description: DV-SSP assistive imaging to collect observational data
Study NCT06315140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: The intervention will build on the 11-year Tribal-academic partnership with the Ramapough Nation of northern NJ to advance tradition-centered farming practices and management strategies supporting sustainable food systems to relieve local food insecurity. Working with the Ramapough-leased Munsee Three Sisters Medicinal farm (growing produce/crops on clean soil) will provide the tribe with nutrition-rich foods and recipes for nutritious cooking. The interventions aims to return healthy soil on the farm allowing for healthy plant production.
Study NCT05787158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy techniques
Description: Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles. (21). Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes
Study NCT05787158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy techniques
Description: Group A: 20 patients were included in this group. This studygroup was assigned with basic treatment protocol with 15 minutes of TENS and thermal therapy for 10 minutes followed by muscle energy technique (Post facilitation stretching exercises). The intervention was given three days per weekfor six weeks. Each total session lasted for 45minutes. METs were applied for the weakened muscles. (21). Group B: 20 Patients of this group were given core stability exercises by the female physical therapist in three different levels. Each level continued for a duration of two weeks in which the patients were trained for the exercises. The patients were provided sessions thrice per week with 2 sets of 10 repetitions and a hold of 10 second after TENS for 15 minutes and thermal therapy for 10 minutes
Study NCT05098106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy, blood sampling; testing.
Description: BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.
Study NCT05761574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Naproxen Sodium Fixed Combination
Description: Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
Study NCT05761574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Naproxen Sodium will be administered orally.
Study NCT05761574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be administered orally.
Study NCT05761574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT05761574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT06461819 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
Description: this researcher used a biodegradable material injection technique. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
Study NCT06183814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG102-031
Description: EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injection.
Study NCT04670003 — intervention group
Intervention type: OTHER
Intervention: users
Description: Data of users of the web-application
Study NCT05147727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole、Famitinib
Description: Fluconazole, once daily on Days 12 to 24; Famitinib, once daily on Days 1 and 15
Study NCT04570813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artistic activies
Description: 12 workshops of artictic activities during 12 weeks
Study NCT06321458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive weight loss intervention
Description: Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication.
Study NCT06321458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study NCT06164847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AERO Program
Description: HEP, identification of barriers for exercise using the COM-B model. Interventions for these barriers: Review of HEP, review of method of delivery, cues, reminders, discussion of barriers and problem solving, motivational interviewing, decision balance sheets, behavioural contract, goal setting reviews, monitoring calls (detailed description in the link below).
Study NCT06164847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: home exercise programs, mobilisations, soft tissue techniques, or training with gym equipment
Study NCT06110806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBIE
Description: MBIE administered over 20 sessions, targets increasing psychological flexibility and acceptance by decreasing avoidance and attempts to control distressing or undesired internal experiences, and includes psychoeducation, targeted mindfulness practice, in vivo exposures, and counter-conditioning.
Study NCT06665204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Practice Guideline-adherent Care
Description: Clinical examination procedures will be used to identify all appropriate impairment subcategories (Overuse/Overload without Other Impairment, PFP with Movement Coordination Deficits, PFP with Muscle Performance Deficits, PFP with Mobility Impairments) and create a subcategory-specific or multimodal (for patients classified to >1 subcategory) plan of care. Research physical therapists will target all applicable impairment subcategories using the corresponding CPG-recommended interventions, all of which are recommended for use as part of standard-of-care physical therapy practice. The duration and length of care will not be prespecified or standardized across participants to allow flexibility pending participant's care needs and schedule (e.g., vacation, short-term TDY status); however, research PTs will be trained to target providing no more than 10-12 visits over no more than 6-8 weeks to promote generalizability of the CPG-adherent intervention.